Tirzepatide's Impact on Birth Control Pill Absorption Investigated in Healthy Women
A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants
Background
Tirzepatide, a novel dual GLP-1 and GIP receptor agonist, has demonstrated remarkable efficacy in the management of type 2 diabetes and obesity, leading to its widespread adoption. As its use expands, particularly among women of reproductive age, understanding potential drug-drug interactions becomes critically important for patient safety and treatment planning. This specific study was designed to evaluate how tirzepatide affects the pharmacokinetics (the processes by which the body absorbs, distributes, metabolizes, and excretes a drug) of a commonly prescribed combined oral contraceptive, ethinylestradiol + norgestimate (EE/NGM).